Two Cycles of High Dose Chemotherapy with Autologous Bone Marrow Support for Patients with Locally Advanced Breast Cancer

E. Randolph Broun, George W. Sledge, David Loesch, Kenneth Cornetta, Robert Hromas, Patricia Kneebone, Chace Lottich, Thomas R. Schmidt, Lawrence H. Einhorn

Research output: Contribution to journalArticle

Abstract

Abstract: Purpose: To examine the impact of two cycles of high dose chemotherapy (HDC) with autologous bone marrow rescue (ABMR) in the treatment of women with locally advanced breast cancer. Patients and Methods: Twenty‐three patients not exhibiting progressive disease to conventional dose therapy (ltx) were eligible for HDC. Conventional dose regimens used were the CAMFTP regimen (n= 6), 5‐FU, doxorubicin and cyclophosphamide (n= 3), cyclophosphamide, methotrexate and 5‐FU (n= 1), or doxorubicin/cyclophosphamide (n= 13). HDC on each cycle consisted of etoposide 625 mg/m2, cyclophosphamide 6 gr/m2, carboplatin 2 gr/m2 with ABMR. Median age of the patients was 40 years. Results: Seventeen patients (74%) underwent two cycles of HDC; 6 received only one cycle due to insurance refusal to pay for C2 (1), toxicity from C1 (4), death on C1(1). There were 2 transplant‐related deaths due to fungal infections 1 each on C1 and C2. Four patients achieved complete remission (CR) with Itx, 18 achieved partial remission (PR), and 1 had stable disease (SD). One patient was converted from PR to CR with HDC. There are 9/23 (39%) patients alive and progression‐free with median follow‐up of 27 months. (range 21‐41 + months). Twelve of the 23 (52%) have progressed at a median of 7 months (range 4‐32) from bone marrow transplant (BMT) and there were 2 early deaths (9%). Six patients received only one cycle of HDC and 2 of these are alive and progression‐free at 36 and 38 months of follow‐up. Of the 17 completing two cycles of HDC, 7/17 (41%) are alive and progression‐free with follow‐up of 21‐41 months. The median progression‐free survival (PFS) for the entire group is 13 months and median overall survival is 21 months (range 1–41 + mos). Conclusion: Despite the use of two cycles of HDC with ABMR, systemic relapse remains the major obstacle to cure in women with locally advanced breast cancer; there is a need to develop more effective preparative rgimens.

Original languageEnglish (US)
Pages (from-to)308-314
Number of pages7
JournalThe Breast Journal
Volume1
Issue number5
DOIs
StatePublished - Sep 1995

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Two Cycles of High Dose Chemotherapy with Autologous Bone Marrow Support for Patients with Locally Advanced Breast Cancer'. Together they form a unique fingerprint.

  • Cite this